Wound Care Biologics Market, By Product Type (Biologic Skin Substitutes, Enzyme Based Formulations, and Growth factors), By Application (Chronic Wounds (Diabetic Foot Ulcers, Venous Leg Ulcers, and Pressure Ulcers) and Acute Wounds ( Surgical Wounds and Burns)), By End User (Hospital, Clinics, Ambulatory Surgical Centers, and Home Care Settings), and By Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Trends, Analysis and Forecast till 2030

The wound care biologics market, which was valued at US$1.66 billion in 2020, is poised for significant growth. With a projected compound annual growth rate (CAGR) of 9.8%, it is expected to reach US$3.88 billion by 2030, indicating a promising future for investors and stakeholders.

Bioengineered products called wound care biologics are applied to lower extremity wounds that do not heal. Applying active biological agents, such as biomolecules derived from plants and animals with antibacterial and antioxidant qualities, is known as wound care biologics. They are used in trauma and post-surgery cases because they offer a moist healing environment that promotes protein and heat loss while preventing bacterial contamination. The use of biologics in wound care has increased dramatically in recent years. Bioengineered products called wound care biologics are applied to lower extremity wounds that do not heal. Additionally, various products are produced to supplement or replace different substrates in the wound-healing cascade. In cases of severe trauma and post-operative care, wound care biologic dressings are becoming more and more popular because they offer a moist healing environment that promotes faster healing by reducing heat loss, protein and electrolyte loss, and bacterial contamination.